Sandra Allen-Bard on Advocating for Patients with Leukemia and Lymphoma

Video

Sandra Allen-Bard discusses her passion for advocacy involvement with the Leukemia & Lymphoma Society.

Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses her involvement in advocacy groups.

Working as a nurse for patients with leukemia for over 20 years, Allen-Bard has gained a passion in seeing how life-altering this diagnosis can be. She believes that research needs to continue as there are different pathways to discover. With the Leukemia & Lymphoma Society, Allen-Bard can use her running, education, and her voice to help her patients in just one more way.

Related Videos
Meaghan Mooney, B.S.N., RN, OCN, during the Extraordinary Healer interview
Colleen O’Leary, DNP, RN, AOCNS, EBP-C, LSSYB, in an interview with Oncology Nursing News.
Michelle H. Johann, DNP, RN, PHN, CPAN, WTA, in an interview with Oncology Nursing News explaining surgical path cards
Alison Tray, of Hartford Healthcare, discusses her team's research on a multidisciplinary team approach to manage the cancer drug shortage
Related Content
Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention

Verbal Workflow for Tocilizumab Orders Results in More Timely CRS Intervention

May 8th 2024
Article

A nurse-driven, verbal workflow to place tocilizumab orders contributed to safer and more effective delivery of tocilizumab for cytokine release syndrome.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma

Acalabrutinib Plus Chemoimmunotherapy Improves PFS in Mantle Cell Lymphoma

May 6th 2024
Article

Patients with untreated mantle cell lymphoma treated with acalabrutinib plus bendamustine and rituximab had significant improvements in progression-free survival compared with bendamustine and rituximab alone.

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

Laura Zitella Discusses the Growing Arsenal of Bispecific Antibodies in DLBCL

December 1st 2023
Podcast

Laura Zitella, MS, RN, ACNP-BC, AOCN, discusses how newly approved bispecific antibodies are expanding third-line treatment options for patients with diffuse large B-cell lymphoma.

Relapsed/Refractory Follicular Lymphoma May Respond to Loncastuximab Tesirine Plus Rituximab

Relapsed/Refractory Follicular Lymphoma May Respond to Loncastuximab Tesirine Plus Rituximab

April 26th 2024
Article

Encouraging responses were observed in most patients with relapsed/refractory follicular lymphoma treated with loncastuximab tesirine and rituximab.

FDA Requires Boxed Warnings for CAR T-Cell Therapies

FDA Requires Boxed Warnings for CAR T-Cell Therapies

April 22nd 2024
Article

All patients treated with CAR T-cell products are recommended to be monitored life-long for the risk of secondary malignancy, according to the FDA.

© 2024 MJH Life Sciences

All rights reserved.